4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,256.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 2,407 shares of the firm’s stock in a transaction on Tuesday, September 23rd. The stock was sold at an average price of $8.00, for a total value of $19,256.00. Following the completion of the sale, the insider directly owned 7,596 shares of the company’s stock, valued at $60,768. The trade was a 24.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $8.39 on Monday. The stock has a market cap of $391.81 million, a P/E ratio of -2.38 and a beta of 2.85. The stock has a 50-day moving average of $6.33 and a two-hundred day moving average of $4.58. 4D Molecular Therapeutics, Inc. has a one year low of $2.23 and a one year high of $11.20.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. Analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on FDMT. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Roth Capital decreased their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, September 13th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.40.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC grew its stake in shares of 4D Molecular Therapeutics by 1,103.4% during the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after buying an additional 367,317 shares during the period. Harbor Capital Advisors Inc. purchased a new position in 4D Molecular Therapeutics in the 1st quarter valued at about $99,000. Two Sigma Investments LP raised its stake in shares of 4D Molecular Therapeutics by 196.3% in the 4th quarter. Two Sigma Investments LP now owns 313,993 shares of the company’s stock valued at $1,749,000 after purchasing an additional 208,021 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of 4D Molecular Therapeutics by 30.1% in the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after purchasing an additional 3,783 shares in the last quarter. Finally, Invesco Ltd. raised its stake in 4D Molecular Therapeutics by 318.3% during the first quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock worth $380,000 after acquiring an additional 89,611 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.